The 3rd Medical Endoscopy Technology Development Conference 2026
On June 4th, 2026, the 3rd Medical Endoscopy Technology Development Conference and the First Medical Surgical Robot Forum successfully concluded at the Hangzhou Dinglan Junshangyunli Hotel. The conference was hosted by You'er Medical Device Service Platform, focusing on two core tracks of minimally invasive medicine, with three special sessions on regulatory requirements and registration, research and development and design manufacturing, and surgical robot forums. It gathered industry experts such as regulatory review specialists, university researchers, complete machine enterprises, optical supply chains, overseas registration agencies, etc., to share valuable insights and attracted practitioners from the national medical device industry to attend. Zhang Chenyang, consulting director of Frost & Sullivan (hereinafter referred to as "Frost & Sullivan"), was invited to attend and deliver a speech.
Zhang Chenyang, consulting director of Frost & Sullivan
Zhang Chenyang pointed out that in recent years, with continuous policy support, continuous breakthroughs in core technologies, continuous expansion of clinical application scenarios, and the gradual recognition of the prognostic advantages of robot-assisted surgery, medical robots are becoming an important force driving the intelligent upgrading of medical services. Currently, the surgical method is gradually evolving from traditional open surgery into an era of robot-assisted minimally invasive surgery.
From the perspective of the policy environment, in recent years, the state has successively issued a number of policy documents such as the "14th Five-Year Plan for the Development of Medical Equipment Industry" and the "Implementation Plan for 'Robot+' Application Actions", accelerating the innovative development of high-end medical equipment. At the same time, the configuration planning of medical robots has been gradually relaxed, the medical insurance payment and charging system has been continuously improved, and Beijing, Shanghai, Hunan and other places have taken the lead in exploring robot-assisted surgery charging and payment, providing important support for the commercialization implementation of the industry.
In terms of market scale, the global surgical robot market has maintained a rapid growth trend. According to Frost & Sullivan's analysis, from 2020 to 2024, the global surgical robot market's compound annual growth rate reached 26.3%; the Chinese market's compound annual growth rate during the same period reached 23.8%. In the future, with the continuous approval of innovative products and the in-depth promotion of clinical applications, the Chinese surgical robot market is expected to enter a new round of high-speed growth cycle, reaching $14.2 billion in 2033, with a compound annual growth rate of 39.3% from 2024 to 2033, and the global market share will continue to increase.
Regardingendoscopic surgical robotsin particular, Zhang Chenyang said that as the most mature sub-track of surgical robots at present, the market scale of Chinese endoscopic robots is expected to grow from $580 million in 2024 to $5.64 billion in 2033, with a compound annual growth rate of 28.7% from 2024 to 2030. At the same time, the industry is showing trends such as AI intelligent planning, 5G remote surgery, and parallel development of single-port and multi-port technologies. As domestic enterprises continue to break through key technologies such as core components, control systems, and visual navigation, the competitiveness of domestic endoscopic robot products is constantly increasing. In the future, it is expected to further increase the coverage rate of primary hospitals and accelerate market penetration.
In addition to endoscopic surgical robots, Zhang Chenyang also focused on introducing orthopedic robots. In the field of orthopedic robots, with the intensification of population aging and the continuous growth in the number of patients with osteoarthritis, spinal diseases, etc., clinical demand has been rapidly released. AI-enabled robots can now achieve preoperative three-dimensional reconstruction, individualized surgical planning, intraoperative precise navigation, and high-precision robotic arm execution, which can alleviate the imbalance between supply and demand of medical service needs and significantly improve surgical precision and safety. It is expected that the market scale of Chinese orthopedic surgical robots will grow from about 800 million yuan in 2024 to 6.4 billion yuan in 2030, with a compound annual growth rate of 41.6% from 2024 to 2030, and the market prospect is broad.
Centering on the international development trend of the industry, Zhang Chenyang further analyzed and pointed out that current Chinese medical robot enterprises are entering an important window period for globalization development. On the one hand, domestic market competition is continuously intensifying, and enterprises need to seek new growth space through overseas market expansion; on the other hand, domestic robots have made remarkable breakthroughs in core technologies, independent intellectual property rights, clinical verification, and product performance, and have gradually gained recognition from international clinical experts. With the continuous growth of global medical robot demand and the active support of national policies for high-end medical equipment going global, Chinese enterprises are expected to occupy a more important position in the global market.
